

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**GENERTEC UNIVERSAL MEDICAL GROUP COMPANY
LIMITED**

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

**ANNOUNCEMENT IN RELATION TO THE PROPOSED PUBLIC
ISSUANCE OF CORPORATE BONDS (TRANCHE 2) IN THE PRC
BY CHINA UNIVERSAL LEASING CO., LTD.,
A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY**

This announcement is made by Genertec Universal Medical Group Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

China Universal Leasing Co., Ltd. (中國環球租賃有限公司) (the “**Issuer**”), a wholly-owned subsidiary of the Company, has received the approval from China Securities Regulatory Commission (the “**CSRC**”) on the issuance of the corporate bonds (the “**Corporate Bonds**”) of an aggregate principal amount up to RMB8 billion to the qualified investors in the People’s Republic of China (the “**PRC**”). As of the date of this announcement, the balance of the principal amount of the Corporate Bonds was RMB6.5 billion. The Corporate Bonds will be issued in several tranches, and the principal amount of the Issuer’s second tranche of the Corporate Bonds in 2025 (the “**T2 Corporate Bonds**”) will not exceed RMB600 million (inclusive). The T2 Corporate Bonds will be in a basic term of five years, at the end of the first year, the second year,

the third year and the fourth year of which the Issuer will be entitled to a repurchase option and a coupon rate adjustment option, while the investors will be entitled to a sell-back option.

The T2 Corporate Bonds will be issued off-line to the qualified investors as defined under the Administrative Measures for the Issuance and Trading of Corporate Bonds (《公司債券發行與交易管理辦法》) by price enquiring and placing.

Other principal terms of the T2 Corporate Bonds to be issued are as follows:

Place of issuance:	The Shanghai Stock Exchange
Par value:	RMB100.00
Issue price:	RMB100.00
Credit rating of the Issuer:	AAA rating for the Issuer
Trading arrangement:	This T2 Corporate Bonds are expected to be issued off-line from 17 January 2025

In accordance with the relevant laws and regulations in the PRC, relevant documents in relation to the Issuer and the T2 Corporate Bonds will be published on the website of The Shanghai Stock Exchange (<http://www.sse.com.cn>). Shareholders of the Company and potential investors are reminded that such documents were prepared in accordance with the requirements in the PRC and are limited solely to the Issuer, and the information contained therein does not provide a full picture of the operation status of the Company and its subsidiaries.

According to the approval from the CSRC, the issuance of the Corporate Bonds will be completed within 24 months from the date of such approval. Further announcement(s) will be made by the Company in relation to the updated progress of issuance of the T2 Corporate Bonds and the issuance of the remaining bonds, if any, as and when appropriate.

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Beijing, PRC, 16 January 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.